Belatacept for early antibody rejection after kidney transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult who has received a kidney transplant.
- You developed a new antibody against your donor kidney (called DSA) after transplant, but your kidney function is still stable.
- You have not had any special treatments for this antibody yet (like IVIG, rituximab, or plasmapheresis).
- You are willing to have a kidney biopsy to check for signs of rejection.
- You are not pregnant, and if you could become pregnant, you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
This trial tests whether a single injection of umbilical cord cells can stop or slow chronic antibody-mediated rejection in kidney transplant patients who haven't improved with standard IV-IG therapy. It aims to reduce damage to the transplanted kidney.
This study is comparing two medications after kidney transplant: Belatacept and anticalcineurins (like tacrolimus). It looks at how each affects blood vessel health. If you are more than a year post-transplant and have stable kidney function, you may be eligible.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.